Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1

Conditions

Neoplasm Metastasis 40Lung Neoplasms 32Multiple Myeloma 24Leukemia, Myeloid, Acute 24Colorectal Neoplasms 23Carcinoma, Non-Small-Cell Lung 20Lymphoma 19Breast Neoplasms 19Urinary Bladder Neoplasms 17Pancreatic Neoplasms 16Prostatic Neoplasms 15Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Melanoma 14Carcinoma, Renal Cell 12Sarcoma 11Glioma 11Carcinoma, Transitional Cell 11Mouth Neoplasms 10Fallopian Tube Neoplasms 10Endometrial Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Neuroblastoma 9Laryngeal Neoplasms 9Glioblastoma 9Carcinoma 9Burkitt Lymphoma 9Stomach Neoplasms 8Oropharyngeal Neoplasms 8Osteosarcoma 7

Interventions

Specimen Handling 3Nivolumab 3Ipilimumab 3Biopsy 3prednylidene 2pembrolizumab 2deltacortene 2Prednisone 2Magnetic Resonance Spectroscopy 2CTLA-4 Antigen 2talimogene laherparepvec 1oblimersen 1cixutumumab 1avelumab 1antineoplaston AS 2-1 1antineoplaston A10 1Tacrolimus 1Sirolimus 1Salts 1Radiosurgery 1Octreotide 1Imatinib Mesylate 1Everolimus 1Complementary Therapies 1Biological Therapy 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Carcinoma, Merkel Cell × Specimen Handling × Clear all
NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT05947500 2026-05-13

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡